The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | |||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | ||||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | FIGI | (to the nearest dollar) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
eFFECTOR Therapeutics Inc | COM | 28202V108 | 1,842,669 | 4,309,329 | SH | SOLE | 4,309,329 | 0 | 0 | |||
NGM Biopharmaceuticals Inc | COM | 62921N105 | 91,046,410 | 18,136,735 | SH | SOLE | 18,136,735 | 0 | 0 | |||
ORIC Pharmaceuticals Inc. | COM | 68622P109 | 21,016,586 | 3,568,181 | SH | SOLE | 3,568,181 | 0 | 0 | |||
RAPT Therapeutics Inc | COM | 75382E109 | 53,076,296 | 2,680,621 | SH | SOLE | 2,680,621 | 0 | 0 | |||
Revolution Medicines Inc | COM | 76155X100 | 109,044,149 | 4,577,840 | SH | SOLE | 4,577,840 | 0 | 0 | |||
Surrozen, Inc. | COM | 86889P109 | 5,478,469 | 9,414,795 | SH | SOLE | 9,414,795 | 0 | 0 | |||
Tenaya Therapeutics, Inc. | COM | 87990A106 | 18,894,583 | 9,400,290 | SH | SOLE | 9,400,290 | 0 | 0 |